

Appendix A

Claim 1- (currently amended):

A method of PDT treatment of cardiovascular indications associated with occlusions of a blood vessel comprising the steps of:
administering a photosensitizer drug other than psoralen compounds; and
delivering intravascular photoactivating light to the blood vessel at an activation wavelength within the range of about 390 to ~~about~~ 610 nm such that the molar extinction coefficient of the photosensitizer drug at the activation wavelength is at least $1000 \text{ L cm}^{-1} \text{ M}^{-1}$.

Claim 2- (previously presented):

The method of claim 1 wherein the photosensitizer drug is texaphyrin or a derivative thereof.

Claim 3 – (previously presented):

The method of claim 2 wherein the photosensitizer drug is lutetium texaphyrin.

Claim 4 – (original):

The method of claim 3 wherein the light is delivered at an activation wavelength within the range of about 457 to about 458 nm.

Claim 5 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a benzoporphyrin or a derivative thereof.

Claim 6 – (original):

The method of claim 5 wherein the light is delivered at an activation wavelength within the range of about 457 to about 458 nm.

Claim 7 – (previously presented):

The method of claim 5 wherein the photosensitizer drug is Visudyne.

Claim 8 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a xanthene or a derivative thereof.

Claim 9 – (original):

The method of claim 8 wherein the photosensitizer drug is Rose Bengal or a derivative thereof.

Claim 10 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is azaporphyrin or a derivative thereof.

Claim 11 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a phthalocyanine or a derivative thereof.

Claim 12 – (original):

The method of claim 1 wherein the photosensitizer drug is a naturally occurring or synthetic porphyrin or a derivative thereof.

Claim 13 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a purpurin or a derivative thereof.

Claim 14 – (original):

The method of claim 1 wherein the photosensitizer drug is a naturally occurring or synthetic chlorin or a derivative thereof.

Claim 15 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a porphycyanine or a derivative thereof.

Claim 16 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is an isomeric porphyrin or a derivative thereof.

Claim 17 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a pentaphyrin or a derivative thereof.

Claim 18 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a sapphyrin or a derivative thereof.

Claim 19 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a phlorin or a derivative thereof.

Claim 20 – (original):

The method of claim 1 wherein the photosensitizer drug is a naturally occurring or synthetic bacteriochlorin or a derivative thereof.

Claim 21 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a benzochlorin or a derivative thereof.

Claim 22 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a hypericin or a derivative thereof.

Claim 23 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is an anthraquinone or a derivative thereof.

Claim 24 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a rhodanol or a derivative thereof.

Claim 25 – (previously presented)

The method of claim 1 wherein the photosensitizer drug is a barbituric acid or a derivative thereof.

Claim 26 – (original):

The method of claim 1 wherein the photosensitizer drug is an expanded porphyrin or a derivative thereof.

Claim 27 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a dipyrromethene or a derivative thereof.

Claim 28 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a coumarin or a derivative thereof.

Claim 29 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is an azo or a derivative thereof.

Claim 30 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is an acridine or a derivative thereof.

Claim 31 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a rhodanine or a derivative thereof.

Claim 32 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is an azine or a derivative thereof.

Claim 33 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a tetrazolium or a derivative thereof.

Claim 34 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a safranine or a derivative thereof.

Claim 35 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is an indocyanine or a derivative thereof.

Claim 36 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is an indigo dye or a derivative thereof.

Claim 37 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a triazine or a derivative thereof.

Claim 38 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a pyrrole derived macrocyclic compound or a derivative thereof.

Claim 39 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a naturally occurring or synthetic isobacteriochlorin or a derivative thereof.

Claim 40 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a naphthalocyanine or a derivative thereof.

Claim 41 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a phenoxazine or a derivative thereof.

Claim 42 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a phenothiazine or a derivative thereof.

Claim 43 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a chaloorganapyrylium or a derivative thereof.

Claim 44 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a triarylmethane or a derivative thereof.

Claim 45 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a rhodamine or a derivative thereof.

Claim 46 – (original):

The method of claim 1 wherein the photosensitizer drug is fluorescein or a derivative thereof.

Claim 47 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a verdin or a derivative thereof.

Claim 48 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is toulidine blue or a derivative thereof.

Claim 49 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is methylene blue or a derivative thereof.

Claim 50 – (original):

The method of claim 1 wherein the photosensitizer drug is methylene violet or a derivative thereof.

Claim 51 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is nile blue or a derivative thereof.

Claim 52 – (original):

The method of claim 1 wherein the photosensitizer drug is nile red or a derivative thereof.

Claim 53 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a phenazine or a derivative thereof.

Claim 54 – (previously presented):

The method of claim 1 wherein the photosensitizer drug is a pinacyanol or a derivative thereof.

Claim 55 – (original):

The method of claim 1 wherein the photosensitizer drug is a plasmocorinth or a derivative thereof.

Claim 56 - (canceled).

Claim 57 - (currently amended):

A method of PDT treatment of cardiovascular indications associated with occlusions of a blood vessel comprising the steps of:

administering a photosensitizer drug; and

delivering a photoactivating light to the blood vessel with a intravascular light delivering device at an activation wavelength within the range of about 440 to about 610 nm such that the molar extinction coefficient of said drug at the activation wavelength is at least $1000 \text{ L cm}^{-1} \text{ M}^{-1}$.

Claim 58 - (previously presented):

The method of claim 1 wherein the photosensitizer drug is a naturally occurring porphyrin induced by an amino-levulinic acid, an amino-levulinic acid ester, an amino-levulinic amide, or derivatives thereof.

Claim 59 - (previously presented):

The method of claim 1 wherein the intravascular photoactivating light is delivered approximately two minutes to forty-eight hours after the administration of the photosensitizer drug.

Claim 60 - (previously presented):

The method of claim 1 wherein the treatment stabilizes or causes a reduction in size of atherosclerotic vulnerable plaques that can result in vessel occlusion if left untreated.